Jesus Martin-Garcia: New Therapies for HERV-Based Disease
Expression from Human Endogenous Retroviruses (HERVs) has been liked to Multiple Sclerosis and Amyotrophic Lateral Sclerosis (ALS) and other neurological diseases. New therapies may slow or possibly reverse disease progression.
Talking Biotech with Dr. Kevin Folta · Colabra
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Human Endogenous Retroviruses (HERVs) comprise 8% of the human genome and are relics of ancient infections, some dating back to pre-human primates. These resident viral elements can be awakened by viral infections, and have been shown to be tightly associated with diseases like Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS). New data suggest a role for HERVs in the neurological symptoms of long COVID. Today's podcast features a conversation with Jesus Martin-Garcia, CEO and Co-Founder of GeNeuro. New therapies target the rogue proteins arising from these ancient viruses, and show promise in treating, if not reversing, disease progression.
Follow GeNeuro on Twitter
GeNeuro Website http://www.geneuro.com/
YouTube Videos of their technology
# COLABRA
Talking Biotech is brought to you by Colabra – an R&D platform that brings your lab’s world-changing research together in one shared space. Learn more at https://www.colabra.app/
# TALKING BIOTECH
Twitter: https://twitter.com/talkingbiotech
Website: https://www.colabra.app/podcasts/talking-biotech/
Instagram: https://www.instagram.com/colabrahq
The Talking Biotech podcast is distinct from Dr. Kevin Folta's teaching and research roles at the University of Florida. The views expressed on the show are those of Dr. Folta and his guests, and do not reflect the opinions of the university or Colabra.